Items 91 ~ 80 of 2176, Page 10 of 272
Merck Completes Tender Offer to Acquire Immune Design
Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30
Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas / Selumetinib Is a MEK 1/2 Inhibitor Being Co-Develop...
Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China
Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Who...
Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2019
Board Authorizes $6 Billion for Share Repurchases
Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and Redemption of Certain Senior Notes